Gamma delta T-cell receptor Vgamma9-Vdelta2 (Vγ9Vδ2 TCR)

The Gamma delta T-cell receptor Vgamma9-Vdelta2 (Vγ9Vδ2 TCR) is a heterodimeric immune receptor uniquely expressed on the majority of circulating human γδ T cells, primarily in peripheral blood, and distinguishes this subset from other T cells. Unlike classical αβ T-cell receptors, the Vγ9Vδ2 TCR recognizes non-peptide antigens called phosphoantigens (pAgs), which are often elevated during infection or cell transformation due to dysregulation of the mevalonate pathway. Recognition of these antigens requires presentation by the butyrophilin (BTN) family molecules, specifically BTN3A1 and BTN2A1. Upon recognition, the Vγ9Vδ2 TCR transmits activation signals that lead to rapid effector responses such as cytokine secretion (notably IFN-γ and TNF-α), direct cytotoxicity against stressed or transformed cells, and the ability to bridge innate and adaptive immunity. Vγ9Vδ2 T cells are a prominent target in cancer immunotherapy due to their broad reactivity against tumor cells and microbes, and their activation can be pharmacologically modulated by aminobisphosphonates like zoledronate, which increase phosphoantigen levels in target cells. While effective, therapeutic approaches targeting Vγ9Vδ2 TCR are limited by challenges surrounding safety, in vivo persistency, and the complexity of the tumor microenvironment[2][4][6][7][8].

Other names

Vγ9Vδ2 TCRGamma delta T-cell receptor Vγ9Vδ2Human Vγ9Vδ2 TCRγδ TCR (Vγ9Vδ2 subset)

Indirect activation via accumulation of phosphoantigens (e.g., isopentenyl pyrophosphate [IPP]) in target cells caused by inhibition of the mevalonate pathway, binding to BTN3A1/BTN2A1, and subsequent TCR engagement[2][4][6][7]; Direct cytotoxicity following TCR recognition triggers cell killing[2][6]; Cytokine release upon TCR engagement[6][8]; Co-stimulatory or inhibitory modulation via receptors like NKG2D, CD27, PD-1, etc.[3][5]